Clinical trials: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
CIDP
Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
This study aims analyze the transcriptome to identify predictive biomarkers of IVIG in CIDP patients. 25 patients with a diagnosis of CIDP according to European criteria, naïve of treatment, will be included and followed for 1…
- Trial name
- BIOMARK (NCT02629796)
- Testing
- CIDP treated (IVIG)
- Where
- 18 sites in France
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Guillain-Barre Syndrome, CIDP
Biomarkers in Polyradiculoneuropathies
The nodes of Ranvier contain ion channels that enable the rapid propagation of the nerve impulse. Cell adhesion molecules and glycolipids play an important role in the formation of the nodes of Ranvier.
- Trial name
- BIP (NCT04249752)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
Chronic Inflammatory Demyelinating Polyneuropathy
Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Participants will be requested to deliver non-invasive vagus nerve stimulation (nVNS) two times per day, at least five days per week.
- Trial name
- NCT03772717
- Testing
- Non-invasive vagus nerve stimulation (nVNS), Standard of care treatment
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Emory University
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
The aim of this study is to learn more about the following treatment options in adults with CIDP: Subcutaneous self-infusion with HyQvia. Intravenous infusion with Gammagard/Kiovig.
- Trial name
- NCT02549170
- Testing
- HYQVIA, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C
- Where
- 83 sites in United States, Argentina and 20 more
- Volunteers
- 138 people
- Sponsor
- Baxalta now part of Shire
Neurological Autoimmune Diseases
IA or PE - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases
In this prospective controlled monocentric observational study, we assessed safety and efficacy of therapy with IA or PE in patients with neurological autoimmune diseases.
- Trial name
- NCT04687332
- Testing
- Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- University Medical Center Mainz
Charcot-Marie-Tooth, CMT1A
Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
The project aims to perform both conventional nerve-conduction studies and axonal-excitability assessments using the TRONDF protocol in patients with selected forms of Charcot-Marie-Tooth disease, with comparison to individuals…
- Conditions
- Charcot-Marie-Tooth, CMT1A, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyneuropathy Associated With Anti-MAG Antibodies (Anti-MAG Polyneuropathy)
- Trial name
- CMT-NFS (NCT07461896)
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The main goal of the study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein once every 3 weeks in people…
- Trial name
- XPERT (NCT07540221)
- Testing
- Gamunex-C, Xembify
- Where
- 15 sites in United States, Czechia and 2 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg.
- Trial name
- VITALIZE (NCT06290141)
- Testing
- riliprubart, IVIg
- Where
- 134 sites in United States, Argentina and 22 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Two Dose Levels of Privigen in Pediatric CIDP
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed…
- Trial name
- NCT03684018
- Testing
- IgPro10
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- CSL Behring
Demyelinating Polyneuropathy
Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg
Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a challenge because disease may generate important disability in patients including young adults.
- Trial name
- PRNC (NCT01349270)
- Testing
- Immunoglobulin perfusion, Prednisone
- Where
- 11 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Trial name
- emvigorate (NCT06920004)
- Testing
- empasiprubart, IVIg
- Where
- 107 sites in United States, Argentina and 29 more
- Volunteers
- 218 people
- Sponsor
- argenx
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barré Syndrome (GBS)
Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy
The aim of this study is to assess disease activity in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Guillain-Barré Syndrome (GBS) using multispectral optoacoustic tomography (MSOT).
- Trial name
- MIND (NCT07121985)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy
The goal of this clinical trial is to learn if ripertamab works to treat chronic inflammatory demyelinating polyneuropathy. It will also learn about the safety of ripertamab.
- Trial name
- RIPERT-CIDP (NCT06858722)
- Testing
- ripertamab
- Volunteers
- 175 people
- Sponsor
- Zhongming Qiu
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
Vitaccess Real CIDP Registry
Vitaccess Real CIDP (VRCIDP) is a patient registry designed to capture longitudinal observational data on chronic inflammatory demyelinating polyneuropathy (CIDP), its treatment, and impact on symptoms, daily activities, and…
- Trial name
- VRCIDP (NCT07006597)
- Volunteers
- 300 people
- Sponsor
- Vitaccess Ltd
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy), CMT (Charcot Marie Tooth Disease)
Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC)
The main purpose of this study is to assess the clinical feasibility of diffusion tensor imaging (DTI) for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- Trial name
- PIDC (NCT03460951)
- Testing
- cervical MRI
- Where
- France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP
This is a multicenter, open-label, single-dose, dose-escalation study evaluating the safety and tolerability of intravenous (IV) KINE-101 in patients with corticosteroid-refractory chronic inflammatory demyelinating…
- Trial name
- NCT07343310
- Testing
- KINE-101
- Where
- 2 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- Kine Sciences Co., Ltd.
Chronic Inflammatory Demyelinating Polyneuropathy
A Registered Cohort Study of Immune-Mediated Neuropathies
This study will provide further insights into the natural course of the disease about Immune-Mediated Neuropathies including clinical features，progression, related antibody spectrum and drug treatment effect.
- Trial name
- NCT04292834
- Where
- 2 sites in China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Chronic Inflammatory Demyelinating Polyneuropathy
Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The investigators are using self administered subcutaneous immunoglobulin (SCIG) in patients with CIDP who require Intravenous immunoglobulin (IVIG). Safety, efficacy, and patient satisfaction will be examined.
- Trial name
- SCIG (NCT02465359)
- Testing
- Immune Globulin Subcutaneous (Human)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of South Florida
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), CIDP
Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The aim of the Pre-Approval Access program is to provide efgartigimod PH20 SC treatment to patients with CIDP who are ineligible to participate in a clinical study and have unmet medical need despite available treatment options.
- Trial name
- NCT04777734
- Testing
- Efgartigimod PH20 SC
- Sponsor
- argenx
Chronic Inflammatory Demyelinating Polyneuropathy
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy
CIDP is a heterogeneous disease with variable responses to therapy. Recently, a distinctive subgroup of patients with serum autoantibodies to the paranodal proteins contactin and neurofascin have been identified.
- Trial name
- NCT04480450
- Testing
- Rituximab
- Sponsor
- University of Kansas Medical Center